

LUNG CANCER SESSION



1 NOVEMBER 2025
(SATURDAY)



08:30 – 16:00 HRS
UAE TIME



IN-PERSON



AL RAS 2

SESSION 1

Chairpersons: Prashant Kumar, India | Asif Shaikh, India | Hala Abd El Latif, UAE

08:30 – 08:40	Opening Remarks
08:40 – 09:00	The Evolving Landscape of Lung Cancer: Highlights from the Past Year David Planchard, France
09:00 – 09:15	Small Cell Lung Cancer – What is new Pongwut Danchaiwijitr, Thailand
09:15 – 09:30	Novel Immunotherapy Approaches in Resectable NSCLC - Checkmate 816 & 77T - <i>Satellite Symposium by BMS</i> Emad Anwar Dawoud, UAE
09:30 – 09:50	Debate: Early-stage NSCLC – Adjuvant therapy vs Neoadjuvant therapy Hassan Shahryar, UAE – Adjuvant Ullas Batra, India – Neoadjuvant
09:50 – 10:20	Early-stage Lung cancer – When and how to combine local and systemic therapy Moderator: Vanita Noronha, India Panelists: Rajiv Kaushal, India Aref Chehal, UAE B.K. Mishra, India Sewanti Limaye, India Ullas Batra, India Fathi Azribi, UAE Lizza Hendriks, Netherlands Ammar Madani, Qatar Mohanad Diab, UAE Rana Irfan Mahmood, UAE Usman Ahmad, UAE Jennifer Leong, Malaysia Roshan Koshy Jacob, UAE
10:20 – 10:40	Evolution of Checkpoint Inhibitors in management of rNSCLC - <i>Satellite Symposium by MSD</i> Ammar Madani, Qatar

10:40 – 11:00 Coffee Break

SESSION 2

Chairperson: Vanita Noronha, India | Dalia ElShorbagy, UAE | Batool Aboud, UAE

11:00 – 11:15	N2 disease in NSCLC – Systemic therapy with Local treatment – How to integrate Lizza Hendriks, Netherlands
11:15 – 11:30	Adjuvant targeted therapy in locally advanced Lung cancer – State of art treatment Mohsen Mokhtar, Egypt
11:30 – 11:50	Debate: Are we ready for monitoring for minimal residual disease in lung cancer Sewanti Limaye, India – Yes Nitesh Rohatgi, India – No

LUNG CANCER SESSION

11:50 – 12:10	From Trial to Treatment: How MARIPOSA-1 is Transforming First-Line EGFRm NSCLC Care - <i>Satellite symposium by Johnson and Johnson</i> Shaheenah Dawood, UAE
12:10 – 12:40	Locally advanced lung cancer – How to choose right combination Moderator: Ullas Batra, India Panelists: Diaeddine Trad, UAE Hassan Shahryar, UAE Aparna Dhar, India Sewanti Limaye, India Ammar Madani, Qatar Hazem Assi, Lebanon Prashant Kumar, India David Planchard, France Muhammad Farooq Latif, UAE Rana Irfan Mahmood, UAE Jennifer Leong, Malaysia Asif Shaikh, India
12:40 – 12:55	Oligometastatic disease – Are they different Hazem Assi, Lebanon
12:55 – 13:05	Q&A
13:05 – 14:05	Lunch Break

SESSION 3

Chairperson: Rana Irfan Mahmood, UAE | Ramanujam Singarachari, UAE

14:05 – 14:20	EGFR mutation positive NSCLC – Do they all require combination therapy Sewanti Limaye, India
14:20 – 15:00	ERBB2, RET, MET, NTRK – How do we diagnose and how do we manage them today Moderator: Akhil Kapoor, India Panelists: Nouri Bennini, UAE Kaltar Das, UAE Vanita Noronha, India Ullas Batra, India Kumar Prabhash, India Hazem Assi, Lebanon Anuj Gupta, India Dorai Ramanathan, UAE Dalia ElShorbagy, UAE Pongwut Danchaivijitr, Thailand Asif Shaikh, India Riyadh Bendardaf, UAE
15:00 – 15:20	Evolving Landscape of ADCs in Lung Cancer David Planchard, France
15:20 – 15:35	Pathology in Lung Cancer – What a clinician should know Rajiv Kaushal, India
15:35 – 16:00	Q&A
16:00	End of Session